Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: Are we counting what counts?

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 216-218

  Pamidi, Sushmita ^b   Mehta, Sanjay ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PROSTACYCLIN; SILDENAFIL; UNIPROST; OXYGEN;

CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; EDITORIAL; EXERCISE; HEMODYNAMICS; HUMAN; PHYSICAL CAPACITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; WALKING; BLOOD; DYSPNEA; ENDURANCE; EXERCISE TEST; EXERCISE TOLERANCE; METHODOLOGY; NOTE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PULMONARY ARTERY; RESPIRATORY FUNCTION; STANDARD; SYSTEMIC SCLEROSIS; TIME;

DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; OUTCOME ASSESSMENT (HEALTH CARE); OXYGEN; PHYSICAL ENDURANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY ARTERY; RESPIRATORY PHYSIOLOGICAL PHENOMENA; SCLERODERMA, SYSTEMIC; TIME FACTORS; WALKING;

EID: 64849084040     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081243     Document Type: Editorial

References (21)

1. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-148
2. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-350 (Pubitemid 36269414)
3. Mukerjee D, St. George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-1093 (Pubitemid 37323574)
4. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24:1626-1631 (Pubitemid 41396463)
5. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-3050 (Pubitemid 44497786)
6. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928 (Pubitemid 46981654)
7. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219 (Pubitemid 34267428)
8. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-1041 (Pubitemid 44684453)
9. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-465
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030
11. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447 (Pubitemid 38187114)
12. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ 1985;132:919-923 (Pubitemid 15066842)
13. American Thoracic Society. ATS Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117
14. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492 (Pubitemid 30129457)
15. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788
16. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-434
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
18. Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-652 (Pubitemid 32492552)
19. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-222 (Pubitemid 46122996)
20. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the six-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009;36:330-336
21. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1999;158:1394-1397